Hope and Healing: Bladder Cancer Awareness Month Starts Today
Breaking Stigmas and Promoting Awareness for Bladder Cancer Save Lives
BCAM is an opportunity for individuals and organizations to come together, fostering a supportive community for those impacted by bladder cancer. Through increased awareness, BCAN aims to break down stigmas associated with the disease while promoting knowledge about its risk factors, symptoms, and the latest treatment options. Raising awareness can drive early detection and ultimately improve outcomes for patients and their loved ones.
This year, BCAN is prioritizing the discussion of risk factors and early signs, educating the public about factors like how quitting smoking lowers the risk of bladder cancer. Additionally, the primary indicator of bladder cancer is blood in the urine. This is never normal and people who notice this symptom should promptly see their doctor.
Throughout May, BCAN will hold various virtual and in-person Walks to End Bladder Cancer, along with other initiatives, to amplify BCAN's message of hope and solidarity. Individuals and organizations are encouraged to join the conversation, share their stories, and support the fight against bladder cancer.
BCAN invites everyone to participate in Bladder Cancer Awareness Month to make a difference in the lives of those impacted by this disease. Together, we can raise awareness, foster a supportive community, and drive progress toward better outcomes for all.
For more information on how you can get involved, please visit BCAN.org.
View original content:https://www.prnewswire.com/news-releases/hope-and-healing-bladder-cancer-awareness-month-starts-today-302133341.html
SOURCE The Bladder Cancer Advocacy Network
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 59th CIFF Guangzhou: Power the Next. Celebrating 30 years, CIFF Guangzhou looks ahead to a new era of design, innovation and global business
- PAINSTUDY Inc. Targets 'Self-Medication' Demand with Functional Muscle and Joint Patches
- Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squ
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share